HK1147674A1 - 作為 受體拮抗劑的雜環化合物 - Google Patents
作為 受體拮抗劑的雜環化合物Info
- Publication number
- HK1147674A1 HK1147674A1 HK11101706.0A HK11101706A HK1147674A1 HK 1147674 A1 HK1147674 A1 HK 1147674A1 HK 11101706 A HK11101706 A HK 11101706A HK 1147674 A1 HK1147674 A1 HK 1147674A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- crth2
- receptor antagonists
- heterocyclic compounds
- crth2 receptor
- heterocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99829807P | 2007-10-10 | 2007-10-10 | |
PCT/US2008/079303 WO2009049021A1 (en) | 2007-10-10 | 2008-10-09 | Heterocyclic compounds as crth2 receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1147674A1 true HK1147674A1 (zh) | 2011-08-19 |
Family
ID=40549546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11101706.0A HK1147674A1 (zh) | 2007-10-10 | 2011-02-22 | 作為 受體拮抗劑的雜環化合物 |
Country Status (13)
Country | Link |
---|---|
US (1) | US8772312B2 (zh) |
EP (1) | EP2197438B1 (zh) |
JP (2) | JP2011500584A (zh) |
KR (2) | KR20130069840A (zh) |
CN (1) | CN101896178B (zh) |
AU (1) | AU2008310874B2 (zh) |
BR (1) | BRPI0815948A2 (zh) |
CA (1) | CA2700824C (zh) |
ES (1) | ES2548577T3 (zh) |
HK (1) | HK1147674A1 (zh) |
IL (1) | IL204823A0 (zh) |
RU (1) | RU2451019C2 (zh) |
WO (1) | WO2009049021A1 (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010008864A2 (en) | 2008-06-24 | 2010-01-21 | Amira Pharmaceuticals, Inc. | Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors |
US8546422B2 (en) * | 2008-09-22 | 2013-10-01 | Merck Canada Inc. | Azaindole derivatives as CRTH2 receptor antagonists |
US8637671B2 (en) | 2008-09-22 | 2014-01-28 | Merck Canada Inc. | Indole derivatives as CRTH2 receptor antagonists |
GB2465062B (en) | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
EP2438059A1 (en) | 2009-06-05 | 2012-04-11 | Link Medicine Corporation | Aminopyrrolidinone derivatives and uses thereof |
AR080703A1 (es) | 2010-03-22 | 2012-05-02 | Actelion Pharmaceuticals Ltd | Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma. |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
WO2012107364A1 (en) * | 2011-02-07 | 2012-08-16 | Scipharm Sàrl | Novel composition for the treatment of cystic fibrosis |
EP2697223B1 (en) | 2011-04-14 | 2016-07-13 | Actelion Pharmaceuticals Ltd. | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
PL3119779T3 (pl) | 2014-03-17 | 2019-01-31 | Idorsia Pharmaceuticals Ltd | Pochodne kwasu azaindolooctowego i ich zastosowanie jako modulatorów receptora prostaglandyny d2 |
RU2016140708A (ru) | 2014-03-18 | 2018-04-18 | Идорсиа Фармасьютиклз Лтд | Производные азаиндол уксусной кислоты и их применение в качестве модуляторов рецептора простагландина d2 |
JP6770522B2 (ja) * | 2015-02-13 | 2020-10-14 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 全身性エリテマトーデスを予防し、及び/又は、治療するためのptgdr−1及び/又はptgdr−2アンタゴニスト |
WO2017005759A1 (en) * | 2015-07-07 | 2017-01-12 | Intervet International B.V. | A process to make azaindole derivatives |
WO2017005764A1 (en) * | 2015-07-07 | 2017-01-12 | Intervet International B.V. | A process to make tricycloketone intermediates of crth2 antagonists |
KR20180053345A (ko) | 2015-09-15 | 2018-05-21 | 이도르시아 파마슈티컬스 리미티드 | 결정질 형태 |
HUE049566T2 (hu) * | 2015-09-29 | 2020-09-28 | Novartis Ag | Eljárás 1-(4-metánszulfonil-2-trifluormetil-benzil)-2-metil-1H-pirrolo- [2,3-B]piridin-3-il-ecetsav elõállítására |
JOP20190223A1 (ar) * | 2017-04-01 | 2019-09-26 | Novartis Ag | عملية لتحضير حمض 1-(4- ميثان سلفونيل -2- تراي فلورو ميثيل - بنزيل)-2- ميثيل -1h- بيرولو [2، 3-b] بيريدين -3- يل- أسيتيك |
JP2022517610A (ja) * | 2019-01-10 | 2022-03-09 | シーエスピーシー ゾンチー ファーマシューティカル テクノロジー(シージアチュアン)カンパニー,リミテッド | 複素環化合物塩およびその使用 |
WO2020143781A1 (zh) * | 2019-01-10 | 2020-07-16 | 石药集团中奇制药技术(石家庄)有限公司 | 作为crth2受体拮抗剂的杂环化合物的晶型 |
CN114502164B (zh) * | 2019-05-22 | 2024-01-26 | 石药集团中奇制药技术(石家庄)有限公司 | 杂环化合物及其盐的应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002302248B2 (en) * | 2001-05-23 | 2008-03-06 | Merck Frosst Canada Ltd. | Dihydropyrrolo[1,2-A]indole and tetrahydropyrido[1,2-A]-indole derivatives as prostaglandin D2 receptor antagonists |
CN1732171A (zh) * | 2002-10-30 | 2006-02-08 | 麦克弗罗斯特(加拿大)公司 | 吡啶并吡咯里嗪和吡啶并吲嗪衍生物 |
EP1558614B1 (en) * | 2002-10-30 | 2010-09-01 | Merck Frosst Canada Ltd. | Pyridopyrrolizine and pyridoindolizine derivatives |
JP4051398B2 (ja) * | 2004-03-11 | 2008-02-20 | アクテリオン ファマシューティカルズ リミテッド | テトラヒドロピリドインドール誘導体 |
JP4708885B2 (ja) * | 2005-07-06 | 2011-06-22 | 日本電気株式会社 | 符号化装置、携帯端末装置及びそれらに用いる画素色情報符号化方法 |
AU2006281937B2 (en) | 2005-08-12 | 2011-11-17 | Merck Canada Inc. | Indole derivatives as CRTH2 receptor antagonists |
US20110112134A1 (en) | 2008-05-16 | 2011-05-12 | Amira Pharmaceuticals, Inc. | Tricyclic Antagonists of Prostaglandin D2 Receptors |
-
2008
- 2008-10-09 WO PCT/US2008/079303 patent/WO2009049021A1/en active Application Filing
- 2008-10-09 KR KR1020137011440A patent/KR20130069840A/ko not_active Application Discontinuation
- 2008-10-09 US US12/681,356 patent/US8772312B2/en active Active
- 2008-10-09 ES ES08838211.4T patent/ES2548577T3/es active Active
- 2008-10-09 BR BRPI0815948A patent/BRPI0815948A2/pt not_active IP Right Cessation
- 2008-10-09 KR KR1020107010092A patent/KR101442663B1/ko active IP Right Grant
- 2008-10-09 CN CN2008801092963A patent/CN101896178B/zh active Active
- 2008-10-09 AU AU2008310874A patent/AU2008310874B2/en active Active
- 2008-10-09 EP EP08838211.4A patent/EP2197438B1/en active Active
- 2008-10-09 CA CA2700824A patent/CA2700824C/en active Active
- 2008-10-09 JP JP2010529022A patent/JP2011500584A/ja active Pending
- 2008-10-09 RU RU2010117156/04A patent/RU2451019C2/ru active
-
2010
- 2010-03-28 IL IL204823A patent/IL204823A0/en unknown
-
2011
- 2011-02-22 HK HK11101706.0A patent/HK1147674A1/zh unknown
-
2013
- 2013-06-19 JP JP2013128863A patent/JP5680146B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP2197438A4 (en) | 2011-10-12 |
KR20130069840A (ko) | 2013-06-26 |
IL204823A0 (en) | 2010-11-30 |
AU2008310874A1 (en) | 2009-04-16 |
CN101896178B (zh) | 2013-11-20 |
JP2013209425A (ja) | 2013-10-10 |
KR20100065398A (ko) | 2010-06-16 |
CA2700824A1 (en) | 2009-04-16 |
EP2197438B1 (en) | 2015-07-15 |
JP2011500584A (ja) | 2011-01-06 |
RU2010117156A (ru) | 2011-11-20 |
EP2197438A1 (en) | 2010-06-23 |
ES2548577T3 (es) | 2015-10-19 |
AU2008310874B2 (en) | 2012-03-15 |
RU2451019C2 (ru) | 2012-05-20 |
JP5680146B2 (ja) | 2015-03-04 |
US20100222270A1 (en) | 2010-09-02 |
BRPI0815948A2 (pt) | 2019-09-24 |
KR101442663B1 (ko) | 2014-09-22 |
CA2700824C (en) | 2013-12-10 |
US8772312B2 (en) | 2014-07-08 |
CN101896178A (zh) | 2010-11-24 |
WO2009049021A1 (en) | 2009-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1147674A1 (zh) | 作為 受體拮抗劑的雜環化合物 | |
HK1244694A1 (zh) | 新穎的胰高血糖素受體拮抗劑 | |
HRP20140384T1 (en) | Indole derivatives as crth2 receptor antagonists | |
EP2346865A4 (en) | INDOIND DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | |
EP2344497A4 (en) | AZAINDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | |
EP2342201A4 (en) | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | |
ZA200909163B (en) | Imidazole derivatives as ccr2 receptor antagonists | |
GB0722216D0 (en) | Use of crth2 antagonist compounds | |
IL201112A0 (en) | Thiazolidine derivatives as orexin receptor antagonists | |
GB0722203D0 (en) | Use of CRTH2 antagonist compounds | |
EP1915372A4 (en) | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | |
EP2215094A4 (en) | HETEROCYCLIC COMPOUNDS WITH N | |
EP2320906A4 (en) | HETEROCYCLIC AMIDE DERIVATIVES AS AN EP4 RECEPTOR ANTAGONISTS | |
ZA200800320B (en) | Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists | |
ZA201006830B (en) | Heterocyclic compounds as adenosine receptor antagonist | |
IL198241A0 (en) | Pyrazoline compounds as mineralocorticoid receptor antagonists | |
EP2161996A4 (en) | CGRP RECEPTOR ANTAGONISTS BASED ON HETEROCYCLIC CARBOXAMIDE | |
IL199430A0 (en) | Crth2 antagonists | |
EP2378877A4 (en) | IMIDAZOLINONE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS | |
ZA200808766B (en) | Nitrated heterocyclic compounds as endothelin receptor antagonist | |
EP2153736A4 (en) | NEW LEUKOTRIEN RECEPTOR ANTAGONIST | |
IL205949A0 (en) | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | |
EP2146712A4 (en) | ANTAGONISTS OF ARYL HETEROCYCLIC CGRP RECEPTORS | |
EP2365748A4 (en) | IMIDAZOISOINDOLA ANTAGONISTS OF NEUROPEPTIDE S RECEPTORS | |
ZA201002171B (en) | 2-s-benzyl substituted pyrimidines as crth2 antagonists |